The Potential of DW-MRI as an Imaging Biomarker in Clinical Trials

摘要: Imaging is increasingly used to inform the drug development process, and provides valuable information from preclinical testing clinical trials. The challenge for imaging techniques yield robust reproducible measurements, which can indicate early treatment response or identify patients who are likely respond treatment. This allows timely decisions be made, so that of most promising drugs accelerated, while curtailing treatments with doubtful benefits. DW-MRI one a number methodologies which, when further developed applied appropriately, could represent major improvement over current other endpoints evaluate success therapy. In this chapter, we discuss challenges faced by modern day review process concept commercialization therapies. important role in discussed, including as potential biomarker surrogate study endpoint, need addressed enable realization such goal.